Precision BioSciences Q2 net loss widens on warrant liability charge

Precision Biosciences

06/08/2026 12:25

Overview
US gene editing firm's Q2 revenue was zero, unchanged from prior period
Q2 net loss widened, mainly due to non-cash warrant liability loss
Company ended Q2 with $112.4 mln in cash, expects runway through 2028

Outlook
Company targets next PBGENE-HBV and PBGENE-DMD clinical updates by year-end 2026
Precision expects existing cash to fund data milestones for PBGENE-HBV and PBGENE-DMD through 2028
Company expects initial safety data from FUNCTION-DMD trial by year-end 2026

Result Drivers
R&D EXPENSES - Decrease in research and development expenses was mainly due to lower platform development and research costs, partially offset by higher PBGENE-DMD and PBGENE-HBV clinical program costs
G&A EXPENSES - General and administrative expenses fell due to operational discipline and lower employee-related costs
WARRANT LIABILITY LOSS - Net loss increased mainly due to non-cash loss from change in fair value of warrant liability

Company press release: ID:nBw9zb3BRa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$1.26
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Precision BioSciences Inc is $20.00, about 167.7% above its August 5 closing price of $7.47

Reuters Recommended Reads
Aug 3 - Switzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion
Aug 5 - Editas Medicine Q2 net loss narrows and beats estimates
Aug 4 - Precigen posts quarterly profit as PAPZIMEOS sales surge

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)